Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Touat

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
International Journal of Radiation Oncology, Biology, Physics|May 17, 2025
INDIGO and Beyond: Approaching Vorasidenib With Cautious OptimismMehdi Touat
Current Opinion in Neurology|November 11, 2022
Editorial: Advances in brain tumors management: new perspectives and challengesMehdi Touat
Neuro-Oncology|January 8, 2025
KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastomaKenan Zhang, Mehdi Touat, Mustafa Khasraw
Current Opinion in Neurology|October 7, 2020
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?Roberta Rudà, Mehdi Touat, Riccardo Soffietti
The New England Journal of Medicine|August 13, 2016
Radiation plus Chemotherapy in Low-Grade GliomaMehdi Touat, Ahmed Idbaih, Marc Sanson
Current Opinion in Neurology|September 10, 2024
Advances in the treatment of IDH-mutant gliomasChooyoung Baek, Alice Laurenge, Mehdi Touat
Current Opinion in Neurology|September 23, 2017
Neurological toxicities associated with immune-checkpoint inhibitorsMehdi Touat, Daniel Talmasov, Damien Ricard, et al.
Current Opinion in Oncology|October 15, 2021
Mutational burden and immune recognition of gliomasDiego Prost, Franck Bielle, Keith L Ligon, et al.
Journal of Blood Medicine|September 14, 2016
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesJohanna Mondesir, Christophe Willekens, Mehdi Touat, et al.
Neuro-Oncology|August 19, 2025
Revisiting an old therapy for new, promising combinations: biology and perspectives of lomustine in glioma treatmentCharlotte Bellamy, Cynthia Hajal, Keith L Ligon, et al.
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
International Journal of Radiation Oncology, Biology, Physics|May 17, 2025
INDIGO and Beyond: Approaching Vorasidenib With Cautious OptimismMehdi Touat
Current Opinion in Neurology|November 11, 2022
Editorial: Advances in brain tumors management: new perspectives and challengesMehdi Touat
Neuro-Oncology|January 8, 2025
KL-50: A novel therapeutic agent targeting MGMT-deficient glioblastomaKenan Zhang, Mehdi Touat, Mustafa Khasraw
Current Opinion in Neurology|October 7, 2020
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?Roberta Rudà, Mehdi Touat, Riccardo Soffietti
The New England Journal of Medicine|August 13, 2016
Radiation plus Chemotherapy in Low-Grade GliomaMehdi Touat, Ahmed Idbaih, Marc Sanson
Current Opinion in Neurology|September 10, 2024
Advances in the treatment of IDH-mutant gliomasChooyoung Baek, Alice Laurenge, Mehdi Touat
Current Opinion in Neurology|September 23, 2017
Neurological toxicities associated with immune-checkpoint inhibitorsMehdi Touat, Daniel Talmasov, Damien Ricard, et al.
Current Opinion in Oncology|October 15, 2021
Mutational burden and immune recognition of gliomasDiego Prost, Franck Bielle, Keith L Ligon, et al.
Journal of Blood Medicine|September 14, 2016
IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesJohanna Mondesir, Christophe Willekens, Mehdi Touat, et al.
Neuro-Oncology|August 19, 2025
Revisiting an old therapy for new, promising combinations: biology and perspectives of lomustine in glioma treatmentCharlotte Bellamy, Cynthia Hajal, Keith L Ligon, et al.
Pageof 11